These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 22101352)

  • 41. Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary.
    Sekiya R; Kajiyama H; Sakai K; Umezu T; Mizuno M; Shibata K; Yamamoto E; Fujiwara S; Nagasaka T; Kikkawa F
    Hum Pathol; 2012 Jun; 43(6):904-10. PubMed ID: 22169254
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
    Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
    Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma.
    Dai F; Zhang Y; Chen Y
    Hum Pathol; 2014 Jun; 45(6):1285-93. PubMed ID: 24767251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decreased ARID1A expression correlates with poor prognosis of clear cell renal cell carcinoma.
    Park JH; Lee C; Suh JH; Chae JY; Kim HW; Moon KC
    Hum Pathol; 2015 Mar; 46(3):454-60. PubMed ID: 25628030
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
    Miše BP; Telesmanić VD; Tomić S; Šundov D; Čapkun V; Vrdoljak E
    Pathol Oncol Res; 2015 Apr; 21(2):347-56. PubMed ID: 25108408
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience.
    Wijaya ST; Ngoi NY; Loh JW; Tan TZ; Lim D; Khan IS; Thian YL; Lai A; Ang BW; Tong P; Ng J; Low JJ; Ilancheran A; Lim SE; Lim YW; Tan DS
    J Gynecol Oncol; 2024 Sep; 35(5):e69. PubMed ID: 38606821
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.
    Xiao W; Awadallah A; Xin W
    Int J Clin Exp Pathol; 2012; 5(7):642-50. PubMed ID: 22977660
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
    Miller RE; Brough R; Bajrami I; Williamson CT; McDade S; Campbell J; Kigozi A; Rafiq R; Pemberton H; Natrajan R; Joel J; Astley H; Mahoney C; Moore JD; Torrance C; Gordan JD; Webber JT; Levin RS; Shokat KM; Bandyopadhyay S; Lord CJ; Ashworth A
    Mol Cancer Ther; 2016 Jul; 15(7):1472-84. PubMed ID: 27364904
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications.
    Chen W; Zhong S; Shan B; Zhou S; Wu X; Yang H; Ye S
    J Ovarian Res; 2020 Aug; 13(1):89. PubMed ID: 32771026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
    Su YF; Tsai EM; Chen CC; Wu CC; Er TK
    Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
    Kuhlmann JD; Wimberger P; Bankfalvi A; Keller T; Schöler S; Aktas B; Buderath P; Hauch S; Otterbach F; Kimmig R; Kasimir-Bauer S
    Clin Chem; 2014 Oct; 60(10):1282-9. PubMed ID: 25015375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.
    Konstantinopoulos PA; Spentzos D; Fountzilas E; Francoeur N; Sanisetty S; Grammatikos AP; Hecht JL; Cannistra SA
    Cancer Res; 2011 Aug; 71(15):5081-9. PubMed ID: 21676886
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy.
    Bamias A; Psaltopoulou T; Sotiropoulou M; Haidopoulos D; Lianos E; Bournakis E; Papadimitriou C; Rodolakis A; Vlahos G; Dimopoulos MA
    Cancer; 2010 Mar; 116(6):1462-8. PubMed ID: 20108307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ARID1A protein expression is retained in ovarian endometriosis with ARID1A loss-of-function mutations: implication for the two-hit hypothesis.
    Yachida N; Yoshihara K; Suda K; Nakaoka H; Ueda H; Sugino K; Yamaguchi M; Mori Y; Yamawaki K; Tamura R; Ishiguro T; Isobe M; Motoyama T; Inoue I; Enomoto T
    Sci Rep; 2020 Aug; 10(1):14260. PubMed ID: 32868822
    [TBL] [Abstract][Full Text] [Related]  

  • 55. X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary.
    Miyamoto M; Takano M; Iwaya K; Shinomiya N; Kato M; Aoyama T; Sasaki N; Goto T; Suzuki A; Hitrata J; Furuya K
    Br J Cancer; 2014 Jun; 110(12):2881-6. PubMed ID: 24853184
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma.
    Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K
    J Surg Oncol; 2006 Apr; 93(5):379-86. PubMed ID: 16550573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma.
    Ohishi Y; Oda Y; Uchiumi T; Kobayashi H; Hirakawa T; Miyamoto S; Kinukawa N; Nakano H; Kuwano M; Tsuneyoshi M
    Clin Cancer Res; 2002 Dec; 8(12):3767-75. PubMed ID: 12473588
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of mitochondrial regulators PGC1α and TFAM as putative markers of subtype and chemoresistance in epithelial ovarian carcinoma.
    Gabrielson M; Björklund M; Carlson J; Shoshan M
    PLoS One; 2014; 9(9):e107109. PubMed ID: 25243473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.